Highlights Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-05-17 pm EDT			5-day change	1st Jan Change
1.6 ^CAD	-1.23%		-3.61%	-35.22%

Mar. 26	Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	CI
Feb. 09	Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	Mar. 26	CI
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results	Feb. 08	MT
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results	Feb. 08	MT
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 07	CI
North American Morning Briefing : Stock Futures Hold Line Ahead of More Earnings, Fedspeak	Feb. 07	DJ
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine	Jan. 08	MT
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections	Jan. 08	CI
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Medexus Pharmaceuticals and Medac GmbH Agree to Amend US Treosulfan Agreement	23-09-28	CI
Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITY	23-08-17	CI
Medexus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
Medexus Jumps Near 14% As Swings To Fiscal Q4 Net Income YOY	23-06-22	MT
Medexus Swings To Fiscal Q4 Net Income YOY	23-06-22	MT
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-21	CI
Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023	23-06-13	CI
Medexus Forecasts Record Revenue for Fiscal Year 2023, Appoints New Board Chair	23-04-11	MT
Medexus Pharmaceuticals Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended March 31, 2023	23-04-11	CI
Medexus Brief: Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 million	23-04-11	MT
Medexus Brief: Expecting Record Revenue for Fiscal Year 2023 and Provides Business Update	23-04-11	MT
Medexus Announces New License Deal for Topical Terbinafine to Treat Fungal Nail Infections	23-03-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Highlights

Filters